Novartis: Data Proves Glivec is Superior Treatment for Patients Newly Diagnosed with Chronic Myeloid Leukemia

BASEL, Switzerland, March 13, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) today announced nearly three-quarters of patients achieve major treatment goal in study comparing Glivec(R) with traditional therapy; Glivec also significantly delays disease progression

Please find press release as an Adobe (.pdf) under the following link http://reports.huginonline.com/895244/114716.pdf